Abstract
IntroductionThere is a strong theoretical rationale for combining checkpoint blockade with cytotoxic chemotherapy in pleural mesothelioma and other cancers. Two recent single-arm, phase 2 trials [DuRvalumab with chEmotherapy as first-line...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have